Heejung Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Heejung Kim has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
- Kyungwon Lee
Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea
18 shared publications - Seok Hoon Jeong
Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea
9 shared publications - Dongeun Yong
Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea
5 shared publications Myungsook Kim
Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea
5 shared publicationsYoung Ah Kim
Department of Laboratory Medicine, National Health Insurance Service, Ilsan Hospital, Goyang, South Korea
5 shared publications- Yoon Soo Park
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
4 shared publications
Latest Publications
- 18 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 364-372
Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales : A Multicenter, Open-Label, Randomized Controlled Trial
Background: Extended-spectrum β-lactamase (ESBL)–producing Enterobacterales are an increasing cause of complicated urinary tract infections (UTIs). Reliance on carbapenems to treat these infections accelerates resistance, underscoring the urgent need for effective oral transition options to preserve last-line agents and lessen healthcare burden. Methods: We conducted a multicenter, open-label, randomized, noninferiority trial at four tertiary hospitals in South Korea (November 2022–June 2025). Adults hospitalized with complicated UTIs due to ESBL-producing Enterobacterales who improved after 3–7 days of intravenous antibiotics were randomized (1:1) to either continue intravenous carbapenem or β-lactam/β-lactamase inhibitor therapy or switch to oral fosfomycin trometamol (3 g once daily). The primary outcome was clinical cure, defined as resolution of urinary tract infection–related symptoms and signs within 4 days after completion of treatment. Secondary outcomes included microbiological cure, readmission, adverse events, and 30-day recurrence. Results: Of the 344 screened patients, 299 were randomized (152 oral fosfomycin; 147 intravenous therapy). Clinical cure occurred in 92.8% of the oral fosfomycin group and 95.2% of the intravenous group (risk difference, −2.47%; 95% CI −7.84 to 2.89), confirming noninferiority. Microbiological cure was similarly high in both groups: urine (98.0% vs 96.6%) and blood (97.3% vs 97.5%). Safety profiles and 30-day outcomes were also comparable. Conclusions: Oral fosfomycin was noninferior to continued intravenous therapy when used as oral transition therapy for complicated UTIs caused by ESBL-producing Enterobacterales. These findings provide evidence to support oral fosfomycin transition as a carbapenem-sparing antibiotic stewardship strategy for patients with complicated UTIs caused by ESBL-producing Enterobacterales. Clinical Trials Registration: KCT0007669.
- 18 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (3) , 364-372
Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales : A Multicenter, Open-Label, Randomized Controlled Trial
Background: Extended-spectrum β-lactamase (ESBL)–producing Enterobacterales are an increasing cause of complicated urinary tract infections (UTIs). Reliance on carbapenems to treat these infections accelerates resistance, underscoring the urgent need for effective oral transition options to preserve last-line agents and lessen healthcare burden. Methods: We conducted a multicenter, open-label, randomized, noninferiority trial at four tertiary hospitals in South Korea (November 2022–June 2025). Adults hospitalized with complicated UTIs due to ESBL-producing Enterobacterales who improved after 3–7 days of intravenous antibiotics were randomized (1:1) to either continue intravenous carbapenem or β-lactam/β-lactamase inhibitor therapy or switch to oral fosfomycin trometamol (3 g once daily). The primary outcome was clinical cure, defined as resolution of urinary tract infection–related symptoms and signs within 4 days after completion of treatment. Secondary outcomes included microbiological cure, readmission, adverse events, and 30-day recurrence. Results: Of the 344 screened patients, 299 were randomized (152 oral fosfomycin; 147 intravenous therapy). Clinical cure occurred in 92.8% of the oral fosfomycin group and 95.2% of the intravenous group (risk difference, −2.47%; 95% CI −7.84 to 2.89), confirming noninferiority. Microbiological cure was similarly high in both groups: urine (98.0% vs 96.6%) and blood (97.3% vs 97.5%). Safety profiles and 30-day outcomes were also comparable. Conclusions: Oral fosfomycin was noninferior to continued intravenous therapy when used as oral transition therapy for complicated UTIs caused by ESBL-producing Enterobacterales. These findings provide evidence to support oral fosfomycin transition as a carbapenem-sparing antibiotic stewardship strategy for patients with complicated UTIs caused by ESBL-producing Enterobacterales. Clinical Trials Registration: KCT0007669.
- Open Access
Changing Trends of Respiratory Viruses in Hospitalized Children During and After the COVID-19 Emergency Phase in Yongin, South Korea (2020–22 vs. 2023–24)
The COVID-19 pandemic and subsequent non-pharmaceutical interventions (NPIs) significantly disrupted the epidemiology of pediatric respiratory viruses. This study compared infection patterns among 3658 hospitalized children in South Korea during the pandemic (2020–2022) and the post-emergency phase (2023–2024), following the relaxation of mandatory NPIs. Of 4419 eligible tests, the most frequently detected viruses overall were rhinovirus/enterovirus (HRV/HEV) (27.9%), influenza (14.5%), and respiratory syncytial virus (RSV, 11.9%). The post-emergency phase was marked by a dramatic surge in influenza virus (IFV), which surged dramatically (5.5% → 28.2%), and a more than two-fold increase in adenovirus (ADV) (5.7% → 12.5%) (p < 0.001). (p < 0.001). Conversely, parainfluenza virus (PIV) detection rates declined significantly (15.4% → 11.3%, p < 0.001). Demographically, post-emergency phase patients were significantly older (mean 4.9 vs. 3.5 years) and experienced a shorter hospital stays (3.2 vs. 4.3 days) (p < 0.001). Crucially, age-specific susceptibility shifts were evident. IFV rebounded across all pediatric ages but spiked severely in school-aged children and adolescents, while HRV/HEV demonstrated a clear proportional shift towards older age groups. These results demonstrate a substantial reconfiguration of the pediatric respiratory landscape, necessitating age-stratified surveillance and flexible public health strategies to mitigate the future infectious disease burden.
Open AccessChanging Trends of Respiratory Viruses in Hospitalized Children During and After the COVID-19 Emergency Phase in Yongin, South Korea (2020–22 vs. 2023–24)
The COVID-19 pandemic and subsequent non-pharmaceutical interventions (NPIs) significantly disrupted the epidemiology of pediatric respiratory viruses. This study compared infection patterns among 3658 hospitalized children in South Korea during the pandemic (2020–2022) and the post-emergency phase (2023–2024), following the relaxation of mandatory NPIs. Of 4419 eligible tests, the most frequently detected viruses overall were rhinovirus/enterovirus (HRV/HEV) (27.9%), influenza (14.5%), and respiratory syncytial virus (RSV, 11.9%). The post-emergency phase was marked by a dramatic surge in influenza virus (IFV), which surged dramatically (5.5% → 28.2%), and a more than two-fold increase in adenovirus (ADV) (5.7% → 12.5%) (p < 0.001). (p < 0.001). Conversely, parainfluenza virus (PIV) detection rates declined significantly (15.4% → 11.3%, p < 0.001). Demographically, post-emergency phase patients were significantly older (mean 4.9 vs. 3.5 years) and experienced a shorter hospital stays (3.2 vs. 4.3 days) (p < 0.001). Crucially, age-specific susceptibility shifts were evident. IFV rebounded across all pediatric ages but spiked severely in school-aged children and adolescents, while HRV/HEV demonstrated a clear proportional shift towards older age groups. These results demonstrate a substantial reconfiguration of the pediatric respiratory landscape, necessitating age-stratified surveillance and flexible public health strategies to mitigate the future infectious disease burden.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (21)
Clinical Approaches to Clostridioides difficile Infection Management: Insights From a Nationwide Survey of Korean Physicians
Moon JM, et al. J Korean Med Sci. 2026 Jun;41:e150. https://doi.org/10.3346/jkms.2026.41.e150
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (21)
Open AccessClinical Approaches to Clostridioides difficile Infection Management: Insights From a Nationwide Survey of Korean Physicians
Moon JM, et al. J Korean Med Sci. 2026 Jun;41:e150. https://doi.org/10.3346/jkms.2026.41.e150
- Open Access
- 30 September 2025
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 47 (3) , 93-97
Evaluation of Various Antimicrobial Susceptibility Tests for Novel β-Lactam/β-Lactamase Inhibitors against Carbapenem-Resistant Pathogens
Young Ah Kim, Choong Soon Lee, Kyoung Ja Jang, and Heejung Kim. Lab Med Qual Assur 2025;47:93-7. https://doi.org/10.15263/jlmqa.2025.47.3.93
- 30 September 2025
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 47 (3) , 93-97
Open AccessEvaluation of Various Antimicrobial Susceptibility Tests for Novel β-Lactam/β-Lactamase Inhibitors against Carbapenem-Resistant Pathogens
Young Ah Kim, Choong Soon Lee, Kyoung Ja Jang, and Heejung Kim. Lab Med Qual Assur 2025;47:93-7. https://doi.org/10.15263/jlmqa.2025.47.3.93
- Open Access
- 20 September 2025
- Published by The Korean Society of Clinical Microbiology in Annals of Clinical Microbiology
- Vol. 28 (3) , 14
Application of diagnostic algorithms for Clostridioides difficile infection using a GDH/ toxin test for five years from a single center in Korea: a diagnostic accuracy study
Background: Accurate diagnosis of Clostridioides difficile infection (CDI) requires both microbiologic confirmation and clinical correlation. Current guidelines recommend a two-step algorithm combining a sensitive screening test with a specific confirmatory assay. This study evaluated the diagnostic performance of the glutamate dehydrogenase (GDH)/toxin enzyme immunoassay (EIA) over five years and assessed its suitability as an initial screening test. Methods: We retrospectively analyzed 8,685 C. difficile-related tests conducted between March 2020 to February 2025. The GDH/toxin EIA was performed using the C. DIFF QUIK CHEK COMPLETE (TechLab). Toxigenic culture involved alcohol-shocked stool samples plated on chromogenic agar and incubated anaerobically for 48 hours. Toxin gene polymerase chain reaction (PCR) was done using the BD MAX Cdiff assay and the Xpert C. difficile assay. Results: The GDH test showed a sensitivity of 77.0% and negative predictive value (NPV) of 95.1% compared with culture. The toxin EIA showed 35.0% sensitivity and 96.9% positive predictive value relative to PCR. The combined GDH+Toxin EIA achieved 82.6% sensitivity and 96.9% NPV compared with PCR. Most discordant results involved low bacterial burden or non-toxigenic isolates. GDH positivity correlated with growth quantity, and toxin EIA positivity varied by ribotype. Algorithm modeling suggested the GDH/toxin test as a cost-effective first-line option. Conclusion: The GDH/toxin EIA demonstrated high NPV and may be appropriate as an initial test in CDI diagnostic algorithms. These findings support its role in diagnostic stewardship and provide evidence to inform the development of national diagnostic guidelines in Korea.
- 20 September 2025
- Published by The Korean Society of Clinical Microbiology in Annals of Clinical Microbiology
- Vol. 28 (3) , 14
Open AccessApplication of diagnostic algorithms for Clostridioides difficile infection using a GDH/ toxin test for five years from a single center in Korea: a diagnostic accuracy study
Background: Accurate diagnosis of Clostridioides difficile infection (CDI) requires both microbiologic confirmation and clinical correlation. Current guidelines recommend a two-step algorithm combining a sensitive screening test with a specific confirmatory assay. This study evaluated the diagnostic performance of the glutamate dehydrogenase (GDH)/toxin enzyme immunoassay (EIA) over five years and assessed its suitability as an initial screening test. Methods: We retrospectively analyzed 8,685 C. difficile-related tests conducted between March 2020 to February 2025. The GDH/toxin EIA was performed using the C. DIFF QUIK CHEK COMPLETE (TechLab). Toxigenic culture involved alcohol-shocked stool samples plated on chromogenic agar and incubated anaerobically for 48 hours. Toxin gene polymerase chain reaction (PCR) was done using the BD MAX Cdiff assay and the Xpert C. difficile assay. Results: The GDH test showed a sensitivity of 77.0% and negative predictive value (NPV) of 95.1% compared with culture. The toxin EIA showed 35.0% sensitivity and 96.9% positive predictive value relative to PCR. The combined GDH+Toxin EIA achieved 82.6% sensitivity and 96.9% NPV compared with PCR. Most discordant results involved low bacterial burden or non-toxigenic isolates. GDH positivity correlated with growth quantity, and toxin EIA positivity varied by ribotype. Algorithm modeling suggested the GDH/toxin test as a cost-effective first-line option. Conclusion: The GDH/toxin EIA demonstrated high NPV and may be appropriate as an initial test in CDI diagnostic algorithms. These findings support its role in diagnostic stewardship and provide evidence to inform the development of national diagnostic guidelines in Korea.
- Open Access
- 1 May 2024
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 30 (5) , 908-915
Identifying Contact Time Required for Secondary Transmission ofClostridioides difficileInfections by Using Real-Time Locating System
Considering patient room shortages and prevalence of other communicable diseases, reassessing the isolation of patients with Clostridioides difficile infection (CDI) is imperative. We conducted a retrospective study to investigate the secondary CDI transmission rate in a hospital in South Korea, where patients with CDI were not isolated. Using data from a real-time locating system and electronic medical records, we investigated patients who had both direct and indirect contact with CDI index patients. The primary outcome was secondary CDI transmission, identified by whole-genome sequencing. Among 909 direct and 2,711 indirect contact cases, 2 instances of secondary transmission were observed (2 [0.05%] of 3,620 cases), 1 transmission via direct contact and 1 via environmental sources. A low level of direct contact (113 minutes) was required for secondary CDI transmission. Our findings support the adoption of exhaustive standard preventive measures, including environmental decontamination, rather than contact isolation of CDI patients in nonoutbreak settings.
- 1 May 2024
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 30 (5) , 908-915
Open AccessIdentifying Contact Time Required for Secondary Transmission ofClostridioides difficileInfections by Using Real-Time Locating System
Considering patient room shortages and prevalence of other communicable diseases, reassessing the isolation of patients with Clostridioides difficile infection (CDI) is imperative. We conducted a retrospective study to investigate the secondary CDI transmission rate in a hospital in South Korea, where patients with CDI were not isolated. Using data from a real-time locating system and electronic medical records, we investigated patients who had both direct and indirect contact with CDI index patients. The primary outcome was secondary CDI transmission, identified by whole-genome sequencing. Among 909 direct and 2,711 indirect contact cases, 2 instances of secondary transmission were observed (2 [0.05%] of 3,620 cases), 1 transmission via direct contact and 1 via environmental sources. A low level of direct contact (113 minutes) was required for secondary CDI transmission. Our findings support the adoption of exhaustive standard preventive measures, including environmental decontamination, rather than contact isolation of CDI patients in nonoutbreak settings.
- Open Access
- 7 March 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (4) , 375-377
A Severe Infection Caused by a White Colony-Producing Strain of Clostridioides difficile RTC41/ST588
Se Yoon Park, M.D., Ph.D., Heejung Kim, M.D., Ph.D., and Yangsoon Lee, M.D., Ph.D.. Ann Lab Med 2024;44:375-7. https://doi.org/10.3343/alm.2023.0474
- 7 March 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (4) , 375-377
Open AccessA Severe Infection Caused by a White Colony-Producing Strain of Clostridioides difficile RTC41/ST588
Se Yoon Park, M.D., Ph.D., Heejung Kim, M.D., Ph.D., and Yangsoon Lee, M.D., Ph.D.. Ann Lab Med 2024;44:375-7. https://doi.org/10.3343/alm.2023.0474
- Open Access
Korean Red Ginseng Potentially Improves Maintaining Antibodies after COVID-19 Vaccination: A 24-Week Longitudinal Study
Despite the effectiveness and safety of COVID-19 vaccines, vaccine-induced responses decline over time; thus, booster vaccines have been approved globally. In addition, interest in natural compounds capable of improving host immunity has increased. This study aimed to examine the effect of Korean Red Ginseng (KRG) on virus-specific antibodies after COVID-19 vaccination. We conducted a 24 week clinical pilot study of 350 healthy subjects who received two doses of the COVID-19 vaccine and a booster vaccination (third dose). These subjects were randomized 1:2 to the KRG and control groups. We evaluated antibody response five times: just before the second dose (baseline), 2 weeks, 4 weeks, 12 weeks after the second dose, and 4 weeks after the third dose. The primary endpoints were changes in COVID-19 spike antibody titers and neutralizing antibody titers. The antibody formation rate of the KRG group was sustained higher than that of the control group for 12 weeks after the second dose. This trend was prominently observed in those above 50 years old. We found that KRG can help to increase and maintain vaccine response, highlighting that KRG could potentially be used as an immunomodulator with COVID-19 vaccines.
Open AccessKorean Red Ginseng Potentially Improves Maintaining Antibodies after COVID-19 Vaccination: A 24-Week Longitudinal Study
Despite the effectiveness and safety of COVID-19 vaccines, vaccine-induced responses decline over time; thus, booster vaccines have been approved globally. In addition, interest in natural compounds capable of improving host immunity has increased. This study aimed to examine the effect of Korean Red Ginseng (KRG) on virus-specific antibodies after COVID-19 vaccination. We conducted a 24 week clinical pilot study of 350 healthy subjects who received two doses of the COVID-19 vaccine and a booster vaccination (third dose). These subjects were randomized 1:2 to the KRG and control groups. We evaluated antibody response five times: just before the second dose (baseline), 2 weeks, 4 weeks, 12 weeks after the second dose, and 4 weeks after the third dose. The primary endpoints were changes in COVID-19 spike antibody titers and neutralizing antibody titers. The antibody formation rate of the KRG group was sustained higher than that of the control group for 12 weeks after the second dose. This trend was prominently observed in those above 50 years old. We found that KRG can help to increase and maintain vaccine response, highlighting that KRG could potentially be used as an immunomodulator with COVID-19 vaccines.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (1) , e9
Vaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants
Kim YC, et al. J Korean Med Sci. 2022 Dec;38(1):e9. https://doi.org/10.3346/jkms.2023.38.e9
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (1) , e9
Open AccessVaccine Effect on Household Transmission of Omicron and Delta SARS-CoV-2 Variants
Kim YC, et al. J Korean Med Sci. 2022 Dec;38(1):e9. https://doi.org/10.3346/jkms.2023.38.e9